Simcere Pharmaceutical Group Limited (SMHGF)

OTCMKTS · Delayed Price · Currency is USD

1.350

-0.139 (-9.34%)

At close: Sep 3, 2026

Market Cap	3.67B -11.1%
Revenue (ttm)	1.28B +22.8%
Net Income	231.37M +81.4%
EPS	0.09 +73.0%
Shares Out	n/a
PE Ratio	15.05
Forward PE	12.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400
Open	1.350
Previous Close	1.489
Day's Range	1.350 - 1.350
52-Week Range	1.350 - 1.960
Beta	0.72
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About SMHGF

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Rα; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clini... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1995

Employees 7,064

Stock Exchange OTCMKTS

Ticker Symbol SMHGF

Financial Performance

In 2025, SMHGF's revenue was 7.73 billion, an increase of 16.52% compared to the previous year's 6.64 billion. Earnings were 1.34 billion, an increase of 86.15%.

Financial numbers in CNY Financial Statements